<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-W0XX47SA</identifier><date>2020</date><creator>Anderluh, Marko</creator><creator>Bratkovič, Tomaž</creator><creator>Jakopin, Žiga</creator><creator>Lunder, Mojca</creator><relation>documents/doc/W/URN_NBN_SI_doc-W0XX47SA_001.pdf</relation><relation>documents/doc/W/URN_NBN_SI_doc-W0XX47SA_001.txt</relation><format format_type="issue">2</format><format format_type="volume">71</format><format format_type="type">article</format><format format_type="extent">str. 152-162</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">21188611</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-W0XX47SA</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Citokini</subject><subject language_type_id="slv">citokinska nevihta</subject><subject language_type_id="slv">imunomodulatorji</subject><subject language_type_id="slv">pandemija covid-19</subject><subject language_type_id="slv">Pandemije</subject><subject language_type_id="slv">SARS-CoV-2</subject><subject language_type_id="slv">sindrom sproščanja citokinov</subject><title>Alleviating cytokine release syndrome in covid-19</title><title>Blaženje sindroma sproščanja citokinov pri covid-19</title></Record>